Environmentally classified pharmaceuticals

Two substances may have the same risk values but different PBT values, but the risk assessment can also be different even if the PBT values are the same. When assessing a medication's environmental impact, consideration should be given to both environmental risk and environmental hazard since bioaccumulation and persistence are not included in the risk assessment.

The Swedish Association of the Pharmaceutical Industry conducted the environmental risk assessment, beginning in 2005.

How to read the table

Last updated: 2010-09-06

« New search


G Genito-urinary system and sex hormones

 Substance  Risk  PBT  P  B  T  Volume in DDD  ATC
Gynecological anti-infectives and antiseptics G01
metronidazole insigni-
ficant
4 3 0 1 221 561 
E 339 795 
G01A F01
A01A B17
D06B X01
J01X D01
P01A B01
clotrimazole cannot be excl  E 581 370 D01A C01
G01A F02
clindamycin cannot be excl 6
N.B.
3
N.B.
0 3
N.B.
217 368 
U 669 318 
D10A F01
D10A F51
G04C B01
J01F F01
ekonazole cannot be excl
E 4 875 970 
G01A F05
D01A C03
D01A C20
Other gynecologicals G02
etonogestrel insigni-
ficant
8
N.B.
3 3 2
N.B.
3 081 000 
C, E 1 578 724 
G03A C08
G02B B01
metylergometrine cannot be excl 7
N.B.
3 3
N.B.
1
N.B.
14 811  G02A B01
atosiban cannot be excl  -  -  -  - 392  G02C X01
dinoprostone cannot be excl  -  -  -  - 7 947  G02A D02
ethinyl estradiol high 9 3 3 3
C 19 843 392 
E 1 578 724 
G02B B01
G03A A03
G03A A05
G03A A07
G03A A09
G03A A11
G03A A13
G03A A12
G03A B03
G03A B04
G03A B05
G03H B01
cabergoline cannot be excl  - - - - 21 040  G02C B03
N04B C06
bromocriptine   9 3 3 3 158 144  G02C B01
N04B C01
metylergometrine cannot be excl 7
N.B.
3 3
N.B.
1
N.B.
14 811  G02A B01
atosiban cannot be excl  -  -  -  - 392  G02C X01
dinoprostone cannot be excl  -  -  -  - 7 947  G02A D02
gemeprost cannot be excl  -  -  -  - G02A D03
cabergoline cannot be excl  - - - - 21 040  G02C B03
N04B C06
carboprost cannot be excl  -  -  -  - 82  G02A D04
quinagolide cannot be excl  -  -  -  - 40 395  G02C B04
Sex hormones and modulators of the genital system G03
desogestrel insigni-
ficant
8
N.B.
3 3 2
N.B.
8 017 128 
C 1 344 868 
G03A A09
G03A B05
G03A C09
etonogestrel insigni-
ficant
8
N.B.
3 3 2
N.B.
3 081 000 
C, E 1 578 724 
G03A C08
G02B B01
estradiol high 9 3 3 3 5 553 012 
C 3 066 7259 
G03C A03
G03F A01
G03F A12
G03F A15
G03F A16
G03F A17
G03F B05
G03F B06
G03F B09
G03F B11
L02A A02
ethinyl estradiol high 9 3 3 3
C 19 843 392 
E 1 578 724 
G02B B01
G03A A03
G03A A05
G03A A07
G03A A09
G03A A11
G03A A13
G03A A12
G03A B03
G03A B04
G03A B05
G03H B01
estriol cannot be excl 6
N.B.
3
N.B.
0 3
N.B.
3 640 342 G03C A04
drospirenone cannot be excl 8
N.B.
3 3
N.B.
2
C 4 037 432 
G03A A12
G03F A17
levonorgestrel cannot be excl 9
N.B.
3 3 3
N.B.
67 866 
C 9 551 024 
G03A A07
G03A B03
G03F B09
norethisterone cannot be excl 9 3 3 3 995 606 
C 3 504 083 
G03A A05
G03A B04
G03A C01
G03D C02
G03F A01
G03F B05
clomiphene cannot be excl  -  -  -  - 212 323  G03B B02
medroxy-
progesterone
cannot be excl - - - - 1 764 361 
C 993 867
L02A B02
G03F A12
G03D A02
G03F B06
G03A C06
mifepristone cannot be excl  -  -  -  - 2 586  G03X B01
progesterone cannot be excl  -  -  -  - E 1 046 203  G03D A04
dienogest insigni-
ficant
4 3 0 1 C 10 752 G03F A15
G03A B
dydrogesterone insigni-
ficant
8 3 3 2 4 500   G03D B01
raloxifene moderate 8 3 3 2 256 730   G03X C01
cyproterone cannot be excl 9
N.B.
3 3 3
N.B.
23 068 
C 553 728 
G03H A01
G03H B01
testosterone cannot be excl 3 0 0 3 685 960  G03B A03
ulipristal cannot be excl  -  -  3  - G03X
lynestrenol cannot be excl  -  -  -  - 1 149 320 
K 85 932
G03A A03
G03A C02
G03D C03
norgestimate cannot be excl  -  -  -  - C 2 451 764 
G03A A11
tibolone cannot be excl  -  -  -  - 826 763  G03C X01
Urologicals G04
sildenafil insigni-
ficant
2 0 0 2 457 158  G04B E03
alfuzosin insigni-
ficant
4
N.B.
3
N.B.
0 1 4 184 342  G04C A01
tadalafil insigni-
ficant
5 3 0 2 422 931  G04B E08
finasteride insigni-
ficant
8 3 3 2 2 343 757  G04C B01
D11A X10
tolterodine cannot be excl 6
N.B.
3
N.B.
0 3
N.B.
1 377 633  G04B D07
solifenacin cannot be excl  -  - 0  - 1 277 095  G04B D08
alprostadil cannot be excl  -  -  -  - 136 731  C01E A01
G04B E01
vardenafil cannot be excl  -  -  -  - 55 720  G04B E09
darifenacin insigni-
ficant
6 3 0 3 299 460  G04B D10
terazosin cannot be excl 6
N.B.
3 0 3
N.B.
536 403  G04C A03
dutasteride cannot be excl 8
N.B.
3 3 2
N.B.
822 840  G04C B02
oxybutynin cannot be excl  -  -  -  - 123 308  G04B D04